Rosenberg Matthew Hamilton Purchases 2,392 Shares of NIKE, Inc. $NKE
by Renee Jackson · The Cerbat GemRosenberg Matthew Hamilton increased its position in shares of NIKE, Inc. (NYSE:NKE – Free Report) by 231.1% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,427 shares of the footwear maker’s stock after buying an additional 2,392 shares during the period. Rosenberg Matthew Hamilton’s holdings in NIKE were worth $243,000 at the end of the most recent reporting period.
Other large investors have also modified their holdings of the company. Brighton Jones LLC boosted its holdings in NIKE by 388.5% in the 4th quarter. Brighton Jones LLC now owns 202,411 shares of the footwear maker’s stock valued at $15,316,000 after purchasing an additional 160,980 shares during the period. GAMMA Investing LLC boosted its holdings in NIKE by 39.1% in the 1st quarter. GAMMA Investing LLC now owns 20,877 shares of the footwear maker’s stock valued at $1,325,000 after purchasing an additional 5,863 shares during the period. Wealth Enhancement Advisory Services LLC boosted its holdings in NIKE by 9.1% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 177,009 shares of the footwear maker’s stock valued at $11,236,000 after purchasing an additional 14,748 shares during the period. Ritholtz Wealth Management boosted its holdings in NIKE by 30.6% in the 1st quarter. Ritholtz Wealth Management now owns 8,939 shares of the footwear maker’s stock valued at $567,000 after purchasing an additional 2,095 shares during the period. Finally, Trust Point Inc. boosted its holdings in NIKE by 17.5% in the 1st quarter. Trust Point Inc. now owns 5,532 shares of the footwear maker’s stock valued at $351,000 after purchasing an additional 822 shares during the period. 64.25% of the stock is owned by institutional investors.
NIKE Trading Up 1.2%
Shares of NKE stock opened at $68.45 on Thursday. NIKE, Inc. has a 12-month low of $52.28 and a 12-month high of $84.76. The company has a market capitalization of $101.18 billion, a P/E ratio of 35.10, a P/E/G ratio of 2.49 and a beta of 1.29. The firm has a 50-day moving average price of $73.38 and a 200 day moving average price of $67.34. The company has a quick ratio of 1.45, a current ratio of 2.19 and a debt-to-equity ratio of 0.59.
NIKE (NYSE:NKE – Get Free Report) last announced its quarterly earnings results on Tuesday, September 30th. The footwear maker reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.22. NIKE had a net margin of 6.23% and a return on equity of 21.16%. The firm had revenue of $11.72 billion during the quarter, compared to the consensus estimate of $10.96 billion. During the same period last year, the firm posted $0.70 EPS. The firm’s quarterly revenue was up 1.0% on a year-over-year basis. Research analysts forecast that NIKE, Inc. will post 2.05 earnings per share for the current fiscal year.
NIKE Announces Dividend
The company also recently declared a quarterly dividend, which was paid on Wednesday, October 1st. Investors of record on Tuesday, September 2nd were issued a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend was Tuesday, September 2nd. NIKE’s dividend payout ratio (DPR) is currently 82.05%.
Wall Street Analysts Forecast Growth
A number of analysts have weighed in on the stock. The Goldman Sachs Group set a $85.00 price target on shares of NIKE and gave the company a “buy” rating in a report on Thursday, September 25th. KeyCorp set a $90.00 price objective on shares of NIKE and gave the company an “overweight” rating in a research note on Thursday, October 2nd. Weiss Ratings upgraded shares of NIKE from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, October 8th. Cowen upgraded shares of NIKE from a “hold” rating to a “buy” rating in a research note on Wednesday, September 10th. Finally, HSBC upgraded shares of NIKE from a “hold” rating to a “buy” rating and set a $80.00 price objective for the company in a research note on Friday, June 27th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-five have given a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $82.21.
Check Out Our Latest Stock Report on NIKE
Insider Activity
In other NIKE news, EVP Treasure Heinle sold 4,300 shares of the firm’s stock in a transaction dated Monday, October 6th. The shares were sold at an average price of $71.27, for a total value of $306,461.00. Following the completion of the sale, the executive vice president owned 29,396 shares in the company, valued at approximately $2,095,052.92. This trade represents a 12.76% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Chairman Mark G. Parker sold 86,078 shares of the firm’s stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $75.93, for a total transaction of $6,535,902.54. Following the completion of the sale, the chairman owned 744,988 shares of the company’s stock, valued at $56,566,938.84. The trade was a 10.36% decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.80% of the company’s stock.
NIKE Company Profile
NIKE, Inc, together with its subsidiaries, designs, develops, markets, and sells athletic footwear, apparel, equipment, accessories, and services worldwide. The company provides athletic and casual footwear, apparel, and accessories under the Jumpman trademark; and casual sneakers, apparel, and accessories under the Converse, Chuck Taylor, All Star, One Star, Star Chevron, and Jack Purcell trademarks.
Recommended Stories
- Five stocks we like better than NIKE
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Palantir’s New Healthcare Deal Boosts AI and Data Reach
- What Are Treasury Bonds?
- GM’s Billion-Dollar Bruise: GM’s Strategic Pivot Makes It a Buy
- Pros And Cons Of Monthly Dividend Stocks
- Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead